The injectable borofalan (10B), independently developed by CNNC Headway, a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) of China. This marks the official entry of the drug into Phase I clinical trials. On January 9, the collaborative clinical project for the Boron Neutron Capture Therapy (BNCT) drug-device combination was officially launched by CNNC Headway, Lanzhou University, Fujian RAYSCO Medical Technology Co Ltd, and Fujian Medical University Union Hospital.

BNCT is a novel, precisely targeted radiotherapy method for cancer cells. It relies on the specific affinity of boron-10 compounds for cancer cells. After the drug accumulates in the tumor site, neutron beam irradiation triggers a boron neutron capture nuclear reaction, thereby precisely destroying tumor cells while maximizing protection for surrounding normal tissues. BNCT has emerged as a highly promising frontier direction in the field of tumor therapy.

The launch of this project is a vivid demonstration of CIRC and its subsidiary CNNC Headway's practice of enterprise-local government collaboration and their promotion of deep integration among industry, academia, and research. It leverages the core advantages of all parties in the BNCT field to form a powerful synergy. CNNC Headway has deep expertise in the nuclear medicine sector. The approved injectable borofalan (10B) will provide the core boron drug for the BNCT treatment system, accelerating the industrial application of BNCT.